Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 4,601–4,700 of 10,906
mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases
Brandi, R., Paganelli, A., D’Amelio, R., Giuliani, P., Lista, F. R., Salemi, S., & Paganelli, R. (2024) · Vaccines · doi:10.3390/vaccines12121418 · Cited by 13
Gelanew, T., Mulu, A., Abebe, M., Bates, T. A., Wassie, L., Teferi, M., Fentahun, D., Alemu, A., Tamiru, F., Assefa, G., et al. (2022) · Vaccines · doi:10.3390/vaccines10060859 · Cited by 14
The current therapeutic cancer vaccines landscape in non‐small cell lung cancer
Chen, S., Cheng, S., Cai, J., Liu, Z., Li, H., Wang, P., Li, Y., Yang, F., Chen, K., & Qiu, M. (2024) · International Journal of Cancer · doi:10.1002/ijc.35088 · Cited by 20
Molecular Targeting of the Most Functionally Complex Gene in Precision Oncology: p53
Brown, D. W., Beatty, P. H., & Lewis, J. D. (2022) · Cancers · doi:10.3390/cancers14215176 · Cited by 13
SARS-CoV-2 vaccine effectiveness in immunosuppressed kidney transplant recipients
Chemaitelly, H., AlMukdad, S., Joy, J. P., Ayoub, H. H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Tang, P., Hasan, M. R., Coyle, P., et al. (2021) · doi:10.1101/2021.08.07.21261578 · Cited by 12
Dulovic, A., Kessel, B., Harries, M., Becker, M., Ortmann, J., Griesbaum, J., Juengling, J., Junker, D., Hernández, P., Gornyk, D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828053 · Cited by 12
Reitemeier, J., Metro, J., & Bohn, P. W. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116457 · Cited by 12
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines and Cutaneous Adverse Reactions: A Review
Alpalhão, M., Silva, J. M., & Filipe, P. (2021) · Dermatitis · doi:10.1097/der.0000000000000755 · Cited by 13
Wojcechowskyj, J. A., Jong, R. M., Mäger, I., Flach, B., Munson, P. V., Mukherjee, P. P., Mertins, B., Barcay, K. R., & Folliard, T. (2025) · npj Vaccines · doi:10.1038/s41541-025-01135-8 · Cited by 15
Levi, Y., Brandeau, M. L., Shmueli, E., & Yamin, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-56561-w · Cited by 16
Harnessing antiviral RNAi therapeutics for pandemic viruses: SARS-CoV-2 and HIV
Bowden-Reid, E., Moles, E., Kelleher, A. D., & Ahlenstiel, C. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01788-x · Cited by 16
Grosso, F. M., Castrofino, A., Castillo, G. D., et al. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.02.003 · Cited by 12
SARS-CoV-2 membrane protein induces neurodegeneration via affecting Golgi-mitochondria interaction
Wang, F., Han, H., Wang, C., Wang, J., Peng, Y., Chen, Y., He, Y., Deng, Z., Li, F., Rong, Y. S., et al. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00458-1 · Cited by 14
Capone, F., Rossi, M., Cruciani, A., Motolese, F., Pilato, F., & Lazzaro, V. D. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.346539 · Cited by 16
The lymphatic system and COVID-19 vaccines
Miyasaka, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1041025 · Cited by 12
Kanjanapan, Y., Blinman, P. L., Underhill, C. R., Karikios, D. J., Segelov, E., & Yip, D. (2021) · Internal Medicine Journal · doi:10.1111/imj.15339 · Cited by 10
McCaughan, G. J. B., Ciaccio, P. R. D., Ananda-Rajah, M. R., Gilroy, N. M., MacIntyre, C. R., Teh, B. W., Weinkove, R., Curnow, J. L., Szer, J., Enjeti, A. K., et al. (2021) · Internal Medicine Journal · doi:10.1111/imj.15247 · Cited by 14
Ou, W., Wang, B., Zhang, G., Ding, L., Liu, Z., Wu, K., Sun, G., Huang, C., Li, Z., Feng, S., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1123385 · Cited by 15
T and B cell responses in different immunization scenarios for COVID-19: a narrative review
Mortari, E. P., Ferrucci, F., Zografaki, I., Carsetti, R., & Pacelli, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1535014 · Cited by 18
Coronavirus disease 2019 in children
Levy, E. R., Blumenthal, J. A., & Chiotos, K. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000762 · Cited by 14
He, Y., Pilkington, E. H., Kang, H. J., Fong, W., Clulow, A. J., Johnston, A. P. R., & Pouton, C. W. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101578 · Cited by 17
“Since 2020, LNPs have been used to deliver mRNA in the COVID-19 vaccines, Comirnaty 2 and Spikevax, 3 which encode variants of the SARS-CoV-2 spike protein.”
SARS-CoV-2 transmission, vaccination rate and the fate of resistant strains
Rella, S. A., Kulikova, Y. A., Dermitzakis, E., & Kondrashov, F. A. (2021) · medRxiv · doi:10.1101/2021.02.08.21251383 · Cited by 6
Identification of Vaccine Effects When Exposure Status Is Unknown
Stensrud, M. J., & Smith, L. H. (2023) · Epidemiology · doi:10.1097/ede.0000000000001573 · Cited by 13
Allan, J., McMillan, D., & Levi, M. L. (2021) · Cureus · doi:10.7759/cureus.20810 · Cited by 12
Global emergence of SARS-CoV-2 variants: new foresight needed for improved vaccine efficacy
Yadav, P. D., & Kumar, S. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00687-3 · Cited by 12
The Key Site Variation and Immune Challenges in SARS-CoV-2 Evolution
Liu, Y., & Ye, Q. (2023) · Vaccines · doi:10.3390/vaccines11091472 · Cited by 12
Giannoccaro, M. P., Vacchiano, V., Leone, M., Camilli, F., Zenesini, C., Panzera, I., Balboni, A., Tappatà, M., Borghi, A., Salvi, F., et al. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11142-7 · Cited by 13
Tucker, M., Azar, M. M., Cohen, E., Gan, G., Deng, Y., Palacios, C. F., & Malinis, M. F. (2022) · Transplant Infectious Disease · doi:10.1111/tid.13876 · Cited by 13
Impact of waning immunity against SARS-CoV-2 severity exacerbated by vaccine hesitancy
Saad-Roy, C. M., Morris, S. E., Boots, M., Baker, R. E., Lewis, B. L., Farrar, J., MARATHE, M. V., Graham, A. L., Levin, S. A., Wagner, C. E., et al. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012211 · Cited by 20
Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials
Aliaga, P. T., Trapani, D., Sandoval, J. L., Crimini, E., Antonarelli, G., Vivanet, G., Morganti, S., Corti, C., Tarantino, P., Friedlaender, A., et al. (2021) · Cancers · doi:10.3390/cancers13225829 · Cited by 11
Is the mRNA COVID-19 Vaccine Safe in Patients With a Prior History of Myocarditis?
Shahid, R., Tang, W. H. W., Klein, A. L., Kwon, D. H., & Amdani, S. M. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.06.011 · Cited by 12
Immunology of RNA-based vaccines: The critical interplay between inflammation and expression
Tregoning, J. S., Wang, Z., Sridhar, S., Shattock, R. J., & DeRosa, F. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.011 · Cited by 25
Imai, K., Tanaka, F., Kawano, S., Esaki, K., Arakawa, J., Nishiyama, T., Seno, S., Hatanaka, K., Sugiura, T., Kodama, Y., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.07.027 · Cited by 12
Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy
Brown, R. B. (2022) · Dialogues in Health · doi:10.1016/j.dialog.2022.100074 · Cited by 11
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infectionwith at least one clinical symptom [31,32].”
Phytochemicals for mitigating the COVID-19 crisis: evidence from pre-clinical and clinical studies
Das, A. M., Khan, S., Roy, S., & Das, S. (2023) · Exploration of Drug Science · doi:10.37349/eds.2023.00024 · Cited by 14
Casmil, I. C., Friesen, J. J., Bathula, N. V., Strumpel, A., Ho, C.-H., Guez, I., Kong, K. Y. S., Varley, A., Miyake-Stoner, S. J., Aliahmad, P., et al. (2025) · Advanced Science · doi:10.1002/advs.202508907 · Cited by 20
Vogrig, M., Berger, A.-E., Bourlet, T., Waeckel, L., Haccourt, A., Chanavat, A. H., Hupin, D., Roche, F., Botelho-Nevers, É., Pozzetto, B., et al. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01354-x · Cited by 14
Acute kidney disease following COVID-19 vaccination: a single-center retrospective study
Chen, C., Yang, S.-S., Hsu, Y., Sung, C., Chu, P., Wu, C., Hsu, S., Wang, H.-E., Lee, D.-J., & Lin, S. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1189243 · Cited by 12
An update on SARS-CoV-2 immunization and future directions
Rana, R., Kant, R., Kumra, T., Gupta, S. V., Rana, D. S., & Ganguly, N. K. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1125305 · Cited by 14
Implementation of mRNA–Lipid Nanoparticle Technology in Atlantic Salmon (Salmo salar)
Dahl, L. O. S., Hak, S., Braaen, S., Molska, A., Rodà, F., Parot, J., Wessel, Ø., Fosse, J. H., Bjørgen, H., Borgos, S. E., et al. (2024) · Vaccines · doi:10.3390/vaccines12070788 · Cited by 17
COVID‐19: An Overview of SARS‐CoV‐2 Variants—The Current Vaccines and Drug Development
Bostanghadiri, N., Ziaeefar, P., Mofrad, M. G., Yousefzadeh, P., Hashemi, A., & Darban‐Sarokhalil, D. (2023) · BioMed Research International · doi:10.1155/2023/1879554 · Cited by 18
Wang, Q., Lv, C., Han, X., Shen, M., & Kuang, Y. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s341429 · Cited by 13
Valera-Rubio, M., Sierra-Torres, M. I., García, R. C., Ramos, J., López-Márquez, M. R., Cruz-Salgado, Ó., & Calleja‐Hernández, M. Á. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2022478 · Cited by 13
Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection
Psichοgiou, M., Karabinis, A., Poulakou, G., Antoniadou, A., Kotanidou, Α., Degiannis, D., Pavlopoulou, I. D., Chaidaroglou, A. S., Roussos, S., Mastrogianni, E., et al. (2021) · Vaccines · doi:10.3390/vaccines9091017 · Cited by 13
Chico-Sánchez, P., Gras-Valentí, P., Algado-Sellés, N., Jiménez-Sepúlveda, N. J., Vanaclocha, H., Peiró, S., Burgos, J. S., Berenguer, A., Navarro, D., & Sánchez–Payá, J. (2022) · Preventive Medicine · doi:10.1016/j.ypmed.2022.107237 · Cited by 12
Sherman, A. C., Crombie, J. L., Cheng, C., Desjardins, M., Zhou, G., Ometoruwa, O., Rooks, R., Senussi, Y., McDonough, M. M., Guerrero, L. I., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac417 · Cited by 15
Self-citationJain, S., Kumar, S., Lai, L., Linderman, S. L., Malik, A. A., Ellis, M. L., Godbole, S., Solis, D., Sahoo, M. K., Bechnak, K., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.03.578771 · Cited by 13
Self-citationAcute Meningoencephalitis after COVID-19 Vaccination in an Adult Patient with Rheumatoid Vasculitis
Senda, J., Ashida, R., Sugawara, K., & Kawaguchi, K. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8815-21 · Cited by 13
Doshi, P., & Fung, K. (2023) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13900 · Cited by 12
Montoya, J. C., Collett, S., Fernandez‐Ruiz, D., Earnest, L., Edeling, M. A., Yap, A. H. Y., Wong, C. Y., Cooney, J. P., Davidson, K. C., Roberts, J., et al. (2024) · Organoids · doi:10.3390/organoids3010002 · Cited by 13
Considerations on the Design of Lipid-based mRNA Vaccines Against Cancer
Meulewaeter, S., Zhang, Y., Wadhwa, A., Fox, K., Lentacker, I., Harder, K. W., Cullis, P. R., Smedt, S. C. D., Cheng, M. H. Y., & Verbeke, R. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168385 · Cited by 13
Model‐Informed Drug Development Applications and Opportunities in mRNA ‐ LNP Therapeutics
Zhou, J., Rao, R. P., Shapiro, M. E., Tania, N., Herron, J. C., Musante, C. J., & Hughes, J. H. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3641 · Cited by 16
Comparison of DNA vaccines with AddaS03 as an adjuvant and an mRNA vaccine against SARS-CoV-2
Neeli, P. K., Chai, D., Wang, X., Sobhani, N., Udeani, G., & Li, Y. (2023) · iScience · doi:10.1016/j.isci.2023.107120 · Cited by 13
Versatile Cell Penetrating Peptide for Multimodal CRISPR Gene Editing in Primary Stem Cells
Graham, J. P., Castro, J. G., Werba, L. C., Amitrano, J., Fardone, L. C., Francis, K. P., Ramamurthi, A., Layden, M. J., McCarthy, H. O., & Gonzalez‐Fernandez, T. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202501532 · Cited by 19
Profiles of US Hispanics Unvaccinated for COVID-19
Piper, B. J., Sanchez, B. V., Madera, J. D., et al. (2022) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-022-01245-2 · Cited by 12
Lin, T.-C., Fu, P., Hsu, Y., & Chen, T. (2023) · Vaccines · doi:10.3390/vaccines11061115 · Cited by 14
Schramm, C. A., Moon, D., Peyton, L., Lima, N. S., Wake, C., Boswell, K. L., Henry, A. R., Laboune, F., Ambrozak, D. R., Darko, S. W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43420-x · Cited by 13
Vaccination and Non-Pharmaceutical Interventions: When Can the UK Relax About COVID-19?Preprint
Moore, S., Hill, E. M., Tildesley, M. J., Dyson, L., & Keeling, M. J. (2021) · medRxiv · doi:10.1101/2020.12.27.20248896 · Cited by 15
Methodological Analysis: Randomized Controlled Trials for Pfizer and Moderna COVID-19 Vaccines
Hallas, D. M., Spratling, R. G., & Fletcher, J. (2021) · Journal of Pediatric Health Care · doi:10.1016/j.pedhc.2021.04.001 · Cited by 13
Li, H., Granger, L. A., Raimi‐Abraham, B. T., Shattock, R. J., Makatsoris, C., & Forbes, B. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125796 · Cited by 17
Long, S., Olsen, R., Christensen, P., et al. (2021) · medRxiv · doi:10.1101/2021.02.26.21252227 · Cited by 2
Covid-19: How independent were the US and British vaccine advisory committees?
Thacker, P. D. (2021) · BMJ · doi:10.1136/bmj.n1283 · Cited by 12
Zaccardelli, A., Wallace, Z. S., & Sparks, J. A. (2023) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000930 · Cited by 14
Monti, S. M., Fornara, C., Delvino, P., Bartoletti, A., Bergami, F., Comolli, G., Sammartino, J. C., Biglia, A., Cassione, E. B., Cassaniti, I., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac365 · Cited by 14
Qiu, X., Yang, Y., Ma, Q., Zheng, B., Chen, Z., Wu, F., Zhou, B., & Xiong, H. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c19387 · Cited by 16
COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey
Lamure, S., Salmanton‐García, J., Robin-Marieton, E., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007357 · Cited by 12
Liu, Z., Skowron, K., Grudlewska‐Buda, K., & Wiktorczyk-Kapischke, N. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.148949 · Cited by 12
A comprehensive review on efficient approaches for combating coronaviruses
Pouresmaieli, M., Ekrami, E., Akbari, A., Noorbakhsh, N., Moghadam, N. B., & Mamoudifard, M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112353 · Cited by 13
Hall, E. J., Ayers, C. R., Kolkailah, A. A., Rutan, C. M., Walchok, J. G., Williams, J. H., Wang, T. Y., Rodríguez, F., Bradley, S. M., Stevens, L. M., et al. (2023) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.122.009652 · Cited by 12
Thrombotic Complications after COVID-19 Vaccination: Diagnosis and Treatment Options
Gütl, K., Raggam, R. B., & Gary, T. (2022) · Biomedicines · doi:10.3390/biomedicines10061246 · Cited by 11
Recent advances in mRNA‐based vaccine for cancer therapy; bench to bedside
Kenoosh, H. A., Pallathadka, H., Hjazi, A. M., Al‐Dhalimy, A. M. B., Zearah, S. A., Ghildiyal, P., Al‐Mashhadani, Z. I., Mustafa, Y. F., Hizam, M. M., & Elawady, A. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3954 · Cited by 16
Adults hospitalized with breakthrough COVID‐19 have lower mortality than matched unvaccinated adults
Myers, L. C., Kipnis, P., Greene, J., Lawson, B. L., Escobar, G. J., FIREMAN, B. H., Klein, N. P., & Liu, V. X. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13504 · Cited by 13
Humoral profiles of toddlers and young children following SARS-CoV-2 mRNA vaccination
Nziza, N., Deng, Y., Wood, L., Dhanoa, N., Dulit-Greenberg, N., Chen, T., Kane, A. S., Swank, Z., Davis, J. P., Demokritou, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45181-7 · Cited by 16
Honda‐Okubo, Y., Antipov, A., André, G. O., Barati, S., Kafi, H., & Petrovsky, N. (2023) · Immunology · doi:10.1111/imm.13661 · Cited by 14
Otolaryngologic Side Effects After COVID ‐19 Vaccination
Ahsanuddin, S., Jin, R., Dhanda, A. K., Georges, K., Baredes, S., Eloy, J. A., & Fang, C. H. (2023) · The Laryngoscope · doi:10.1002/lary.30923 · Cited by 16
O’Neill, A., Mantri, C. K., Tan, C. W., Saron, W. A. A., Nagaraj, S. K., Kala, M. P., Joy, C. M., Rathore, A. P. S., Tripathi, S., Wang, L., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104924 · Cited by 12
Palandri, F., Breccia, M., Stefano, V. D., & Passamonti, F. (2021) · Cancers · doi:10.3390/cancers13194750 · Cited by 13
Structural characterization of mRNA lipid nanoparticles (LNPs) in the presence of mRNA-free LNPs
Chen, X., Ye, Y., Li, M., Zuo, T., Xie, Z., Ke, Y., Cheng, H., Hong, L., & Liu, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114082 · Cited by 23
Chu, C., Schönbrunn, A., Fischer, D., Liu, Y., Hocher, J.-G., Weinerth, J., Klemm, K., von Baehr, V., Krämer, B. K., Elitok, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1187880 · Cited by 13
Podrazil, M., Táborská, P., Stakheev, D., Rataj, M., Lašťovička, J., Vlachova, A., Pohunek, P., Bartůňková, J., & Smrž, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.892277 · Cited by 13
Dugani, S. B., Fischer, K. M., Schroeder, D. R., Geyer, H. L., Maniaci, M. J., Croghan, I. T., Kashani, D., & Burton, M. C. (2022) · Journal of Hospital Medicine · doi:10.1002/jhm.12812 · Cited by 11
van Doremalen, N., Schulz, J. E., Adney, D. R., Saturday, T. A., Fischer, R., Yinda, C., Thakur, N., Newman, J., Ulaszewska, M., Belij-Rammerstorfer, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1343927/v1 · Cited by 14
Matsuura, T., Fukushima, W., Nakagama, Y., Kido, Y., Kase, T., Kondo, K., Kaku, N., Matsumoto, K., Suita, A., Mukai, E., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-57931-0 · Cited by 14
Long-term adaptive response in COVID-19 vaccine recipients and the effect of a booster dose
Perico, L., Todeschini, M., Casiraghi, F., Mister, M., Pezzotta, A., Peracchi, T., Tomasoni, S., Trionfini, P., Benigni, A., & Remuzzi, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1123158 · Cited by 15
Meyer, M., Wang, Y., Edwards, D. K., Smith, G. R., Rubenstein, A. B., Ramanathan, P., Mire, C. E., Pietzsch, C. A., Chen, X., Ge, Y., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.25.428136 · Cited by 12
Self-citationVollenberg, R., Tepasse, P., Lorentzen, E. U., & Nowacki, T. M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050694 · Cited by 12
Goldman, J. D., Gonzalez, M. A., Rüthrich, M. M., Sharon, E., & von Lilienfeld‐Toal, M. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_359656 · Cited by 14
Ueno, M., Takabatake, H., Itakura, J., Fujita, R., Kayahara, T., Morimoto, Y., Notohara, K., & Mizuno, M. (2023) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-023-01794-x · Cited by 14
Vázquez, N. M., García-Studer, A., Rojas-Gimenez, M., Romero-Barco, C. M., Arija, S. M., Mucientes, A., Velloso-Feijoó, M. L., Godoy‐Navarrete, F. J., Morales-Garrido, P., Redondo‐Rodríguez, R., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092437 · Cited by 12
Does COVID-19 Vaccination Warrant the Classical Principle “ofelein i mi vlaptin”?
Doulberis, M., Papaefthymiou, A., Kotronis, G., Gialamprinou, D., Soteriades, E. S., Kyriakopoulos, A. M., Chatzimichael, E., Kafafyllidou, K., Liatsos, C. N., Chatzistefanou, I., et al. (2021) · Medicina · doi:10.3390/medicina57030253 · Cited by 15
Quelling Public Fears About Guillain-Barré Syndrome and COVID-19 Vaccination
BOURDETTE, D. N., & Killestein, J. (2021) · Neurology · doi:10.1212/wnl.0000000000011882 · Cited by 13
Qi, X., Wang, J., Zhang, Q., Ai, J., Liu, C., Li, Q., Gu, Y., Lv, J., Huang, Y., Liu, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27992 · Cited by 12
COVID outbreak after the 1st dose of COVID vaccine among the nursing home residents: What happened?
Ye, P., Fry, L., Liu, H., Ledesma, S., & Champion, J. D. (2021) · Geriatric Nursing · doi:10.1016/j.gerinurse.2021.06.022 · Cited by 11
Saunders, K. O., Lee, E., Parks, R., Martinez, D. R., Li, D., Chen, H., Edwards, R. J., Gobeil, S., Barr, M., Mansouri, K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.17.431492 · Cited by 14
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.